News
TLTFF
0.193
NaN%
--
Weekly Report: what happened at TLTFF last week (0223-0227)?
Weekly Report · 2d ago
Weekly Report: what happened at TLTFF last week (0216-0220)?
Weekly Report · 02/23 09:33
Correcting and Replacing: Theralase Bladder Cancer Clinical Data to be Presented at the 2026 European Association of Urology Congress
Newsfile · 02/20 12:00
Theralase Bladder Cancer Clinical Data to be Presented at the 2026 European Association of Urology Congress
Newsfile · 02/17 12:00
Weekly Report: what happened at TLTFF last week (0209-0213)?
Weekly Report · 02/16 09:32
Theralase(R) Bladder Cancer Clinical Data to be Presented at the 2026 American Urological Association Annual Meeting
Newsfile · 02/10 12:00
Weekly Report: what happened at TLTFF last week (0202-0206)?
Weekly Report · 02/09 09:34
Theralase Technologies meldet erfolgreiche Phase-II-Studie bei Blasenkrebs
Reuters · 02/04 12:03
Theralase Technologies Reports Positive Phase II Bladder Cancer Trial Results
Reuters · 02/04 12:03
Theralase(R) Provides Update on Bladder Cancer Clinical Study
Newsfile · 02/04 12:00
Weekly Report: what happened at TLTFF last week (0126-0130)?
Weekly Report · 02/02 09:33
Weekly Report: what happened at TLTFF last week (0119-0123)?
Weekly Report · 01/26 09:33
Weekly Report: what happened at TLTFF last week (0112-0116)?
Weekly Report · 01/19 09:36
Theralase Technologies and Ferring Pharmaceuticals Launch Clinical Collaboration for Bladder Cancer Therapy
Reuters · 01/12 12:02
Ferring Pharmaceuticals and Theralase(R) Technologies Announce Clinical Development Agreement to Investigate Combination Therapy in Bladder Cancer
Newsfile · 01/12 12:00
Weekly Report: what happened at TLTFF last week (0105-0109)?
Weekly Report · 01/12 09:35
Theralase Technologies Inc. Trading Halted on TSX Venture
Reuters · 01/09 20:57
Weekly Report: what happened at TLTFF last week (1229-0102)?
Weekly Report · 01/05 09:33
Weekly Report: what happened at TLTFF last week (1222-1226)?
Weekly Report · 12/29/2025 09:32
Theralase(R) closes $1.3M non-brokered private placement
Seeking Alpha · 12/23/2025 21:53
More
Webull provides a variety of real-time TLTFF stock news. You can receive the latest news about Theralase Technologies Inc through multiple platforms. This information may help you make smarter investment decisions.
About TLTFF
Theralase Technologies Inc. is a Canada-based clinical stage pharmaceutical company. The Company is engaged in the research and development of light, radiation, sound and drug-activated small molecule compounds and their associated formulations, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses, with minimal impact on surrounding healthy tissue. It operates through two divisions: the Drug Division and the Device Division. The Drug Division is responsible for the research and development of small molecules primarily for the treatment of cancer with assistance from the Device Division to develop medical lasers to activate them. The Device Division is responsible for the Company’s medical laser business, which researches, develops, manufactures and distributes cool laser therapy systems to healthcare practitioners, predominantly for the healing of pain.